When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IPSEF - EMA accepts Ipsen's marketing application for Cabometyx for liver cancer
Ipsen Sa Ord
Exelixis (NASDAQ:EXEL) announces that the European Medicines Agency (EMA) has accepted for review collaboration partner Ipsen's (OTCPK:IPSEY)(OTCPK:IPSEF) marketing application seeking approval for CABOMETYX (cabozantinib) for previously treated patients with advanced hepatocellular carcinoma.
More news on: Exelixis, Inc., Ipsen S.A. ADR, Ipsen S.A., Healthcare stocks news,